Misplaced Pages

Nandrolone nonanoate

Clinical data
Other names	19-Nortestosterone 17β-nonanoate; Nandrolone pelargonate; 19-Nortestosterone 17β-pelargonate
Drug class	Androgen; Anabolic steroid; Androgen ester; Progestogen
Identifiers
IUPAC name phenanthren-17-yl] nonanoate
CAS Number	52230-64-5
UNII	2B78GY4XY5
Chemical and physical data
Formula	C27H42O3
Molar mass	414.630 g·mol
3D model (JSmol)	Interactive image
SMILES CCCCCCCCC(=O)O1CC23CCC4=CC(=O)CC43CC12C
InChI InChI=1S/C27H42O3/c1-3-4-5-6-7-8-9-26(29)30-25-15-14-24-23-12-10-19-18-20(28)11-13-21(19)22(23)16-17-27(24,25)2/h18,21-25H,3-17H2,1-2H3/t21-,22+,23+,24-,25-,27-/m0/s1 AuxInfo=1/0/N:1,30,2,3,4,5,6,7,8,18,23,17,24,14,13,27,28,20,19,21,25,26,16,15,12,9,29,22,10,11/it:im/rA:30CCCCCCCCCOOCCCCCCCCCCOCCCCCCCC/rB:s1;s2;s3;s4;s5;s6;s7;s8;d9;s9;p11;s12;s13;p14;s15;N16;s17;s18;d19;s20;d21;s21;s23;s19n24;s16s25;P26;s27;s12s15s28;P29;/rC:-11.2241,.7601,0;-9.8904,-.0099,0;-8.5567,.7601,0;-7.223,-.0099,0;-5.8893,.7601,0;-4.5557,-.0099,0;-3.222,.7601,0;-1.8883,-.0099,0;-.5546,.7601,0;-.5546,2.3001,0;.7791,-.0099,0;2.1127,.7601,0;2.2737,2.2917,0;3.7801,2.6118,0;4.5501,1.2782,0;6.0564,.958,0;7.0869,2.1024,0;8.5932,1.7822,0;9.0691,.3176,0;10.5754,-.0026,0;11.0513,-1.4672,0;12.5577,-1.7874,0;10.0209,-2.6117,0;8.5145,-2.2915,0;8.0386,-.8268,0;6.5323,-.5067,0;5.5018,-1.6511,0;3.9955,-1.3309,0;3.5196,.1337,0;2.3751,-.8967,0; Key:UVVFTQBZOQSECA-QNTYDACNSA-N

Nandrolone nonanoate, also known as nandrolone pelargonate or as 19-nortestosterone 17β-nonanoate, is an androgen and anabolic steroid and an androgen ester—specifically, the C17β nonanoate (pelargonate) ester of nandrolone (19-nortestosterone)—which was studied but was never marketed.

References

1. Chaudry AQ, James KC (February 1974). "A Hansch analysis of the anabolic activities of some nandrolone esters". J Med Chem. 17 (2): 157–61. doi:10.1021/jm00248a003. PMID 4809250.
2. Chaudry MA, James KC, Ng CT, Nicholls PJ (December 1976). "Anabolic and androgenic activities, in rat, of some nandrolone and androstanolone esters". J Pharm Pharmacol. 28 (12): 882–5. doi:10.1111/j.2042-7158.1976.tb04085.x. PMID 12263. S2CID 20546783.
3. Chaudry MA (1983). "Preparation and characterization some of anabolic steroids". Journal of Pharmacy (Lahore). 4 (1–2): 13–17. ISSN 0253-8288. Butyrate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, and undecanoate esters of testosterone and nandrolone were prepd. and characterized.
4. Chaudry MA (1983). "A realistic method for the evaluation of anabolic androgenic activity of some nandrolone esters". Journal of Pharmacy (Lahore). 4 (1–2): 51–62. ISSN 0253-8288. The short-comings of the various methods used for detg. anabolic-androgenic activities were discussed, and a realistic method was developed for the comparative studies. The limitation of using the wt. gain of the target organs after administration of the hormone, which is time-dependent, was highlighted. The cumulative wt. (mg day) was recommended; it is independent of time, provided the expt. is carried out until the sample response reaches a plateau. This method provides a basis for obtaining anabolic-androgenic percentage dissocn. The method is applied to a no. of nandrolone esters.
5. Ruelle P, Farina-Cuendet A, Kesselring UW (November 1997). "The mobile order solubility equation applied to polyfunctional molecules: The non-hydroxysteroids in aqueous and non aqueous solvents". Int J Pharm. 157 (2): 219–232. doi:10.1016/s0378-5173(97)00240-8. PMID 10477819.
6. Joseph R. Robinson (1978). Sustained and Controlled Release Drug Delivery Systems. M. Dekker. p. 428. ISBN 978-0-8247-6715-0.
7. Chien YW (1981). "Long-acting parenteral drug formulations". J Parenter Sci Technol. 35 (3): 106–139. PMID 6113276.

• Abandoned drugs
• Alkene derivatives
• Anabolic–androgenic steroids
• Enones
• Nonanoate esters
• Nandrolone esters
• Progestogens